Investors Seek Justice: Hims & Hers Faces Class Action Over Business Misconduct Allegations

A Call for Accountability: Hims & Hers' Legal Challenges

In recent developments, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself in hot water as investors step forward amidst claims of major financial losses. The company, well-known for its telehealth and wellness services, is currently facing a class action lawsuit rooted in allegations presented by the Federal Trade Commission (FTC) that suggest serious misconduct involving business practices and customer data handling.

Background of the Allegations

The foundation of the current securities class action lies in a sweeping complaint filed by the FTC on July 29, 2026. The litigation accuses Hims & Hers and specific executives of misleading investors by disseminating false statements about their handling of health information and business operations. According to the FTC, the company purportedly assured investors of maintaining stringent policies regarding user data security while concurrently sharing sensitive health information with third-party advertisers such as Meta Platforms and Snap.

The complaint outlines several key issues, asserting that Hims & Hers violated consumer trust by:
1. Sharing Health Information: Despite promoting their services as secure and private, Hims allegedly transmitted personal health data to advertising platforms through the use of tracking pixels.
2. Questionable Billing Practices: Consumers were reportedly charged for their medications immediately upon submitting intake forms, without consulting a healthcare provider as previously assured.
3. Lack of Regulatory Compliance: The company is accused of failing to adhere to legal standards set by the Restore Online Shoppers' Confidence Act (ROSCA), leading to consumers being enrolled in subscription models without clear consent.

Market Reaction

Following the FTC’s announcement, Hims & Hers saw a drastic decline in its stock prices, plummeting by 14.7% in a single day, which erased nearly $970 million from its market value. This significant drop has raised concerns among current investors regarding the company's commitment to transparency and ethical business practices. Reed Kathrein, partner at Hagens Berman, the firm leading this class action, emphasized the importance of investigating whether Hims had intentionally misled its investors about its internal controls and the financial implications of the alleged wrongdoings.

Class Action Details

Investors who have experienced substantial losses between August 4, 2025, and July 29, 2026, are encouraged to voice their experiences and potentially join the lawsuit. The deadline for filing as a lead plaintiff in this class action is set for November 2, 2026.

As Hagens Berman continues to gather evidence, they are also reaching out to whistleblowers who could shed light on misconduct within Hims & Hers. The firm highlights the opportunity under the SEC Whistleblower program, which may reward individuals for providing original information leading to a successful recovery.

Final Thoughts

This situation underscores the crucial need for companies, especially those handling sensitive health data, to uphold the highest standards of integrity and transparency. As the legal proceedings continue, Hims & Hers Health will have to confront not only its operational accountability but also its fundamental commitment to its investors and the consumers it serves. Investors are reminded to stay informed and vigilant in their pursuit of justice and corporate accountability.

For those wanting to engage further or offer insights into Hims & Hers' practices, Hagens Berman invites you to reach out via their investigation page or contact details provided.